Guggenheim Starts Rapport Therapeutics (RAPP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts RAPP Hot Sheet
Price: $32.19 +0.06%
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 35
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 35
Join SI Premium – FREE
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Buy rating and a price target of $65.00.
For an analyst ratings summary and ratings history on Rapport Therapeutics click here. For more ratings news on Rapport Therapeutics click here.
Shares of Rapport Therapeutics closed at $32.17 yesterday.
You May Also Be Interested In
- Goldman Sachs Reinstates Hitachi Construction Machinery Co Ltd (6305:JP) (HTCMY) at Sell
- Baird Starts Modine Manufacturing (MOD) at Outperform
- Guggenheim Assumes Xenon Pharmaceuticals (XENE) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
